3,561 Becton, Dickinson and Company $BDX Shares Sold by Third View Private Wealth LLC

Third View Private Wealth LLC lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 13.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,922 shares of the medical instruments supplier’s stock after selling 3,561 shares during the period. Third View Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $4,103,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Becton, Dickinson and Company during the 2nd quarter valued at approximately $3,721,533,000. State Street Corp raised its holdings in Becton, Dickinson and Company by 8.5% during the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock worth $2,269,960,000 after purchasing an additional 1,177,256 shares during the last quarter. First Eagle Investment Management LLC lifted its position in shares of Becton, Dickinson and Company by 15.8% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares during the period. Bank of America Corp DE acquired a new position in shares of Becton, Dickinson and Company in the 2nd quarter worth approximately $474,993,000. Finally, Legal & General Group Plc boosted its stake in shares of Becton, Dickinson and Company by 1.5% in the 2nd quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier’s stock valued at $318,050,000 after purchasing an additional 30,766 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Michael Feld sold 165 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,907 shares of company stock worth $1,269,128 over the last quarter. 0.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BDX has been the subject of a number of analyst reports. Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a research note on Thursday, August 13th. TD Cowen increased their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Bank of America increased their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Finally, Zacks Research raised Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $185.07.

Becton, Dickinson and Company Price Performance

BDX stock opened at $197.88 on Wednesday. The stock has a market capitalization of $54.52 billion, a PE ratio of 59.60, a price-to-earnings-growth ratio of 13.39 and a beta of 0.22. The company’s 50-day moving average is $186.86 and its 200-day moving average is $170.20. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $200.47.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.